

# Respiratory Viruses in Luxembourg (ReViLux)

Weekly report (Period 28/06/-04/07/2021)



## Executive Summary

The aim of the “Sentinel” national surveillance program is to monitor the circulating respiratory viruses, including SARS-CoV-2 variants, and hence underpin public health actions.

In week 26/2021, the variant P.1 (Gamma) became the dominant one with an overall frequency of 72,4% (CI 68,6% - 76,2%,  $p < 0,05$ ) in all sequenced specimens, followed by the B.1.617.2 (Delta) variant with 25,4% (CI 21,7% - 29,1%,  $p < 0,05$ ) and the B.1.1.7 (Alpha) variant with 1,1% (CI 0,2% - 2%,  $p < 0,05$ ).

The representative sample size was estimated, based on the number of positive cases in Luxembourg for week 26 (787). The minimum sample size required to detect prevalence of B.1.617.2 (60,8%) reported in week 25, with an error margin of 5%, was estimated to be 251 specimens. This number corresponds to a coverage of 31,9%, which exceeds the minimum coverage recommended by ECDC (10%). The sequencing results of week 24 are not representative of the circulating variants in Luxembourg with an error margin of 5%.

The total number of sequences performed this week was 637, with 540 specimens having been collected in the time frame of week 26/2021. The sequencing coverage - based on sequenced samples collected in week 26 and corresponding to Luxembourg residents - was 65,1% of all positive cases in Luxembourg.



## Clinical Surveillance

The “Sentinel” surveillance network reported 290 consultations in week 26 (28/JUNE/2021 - 04/JULY/2021). No cases of ILI<sup>1</sup> have been reported as shown in **Figure 1**. The number of consultations for ARI<sup>2</sup> was 25, which represents 8,6%.




Figure 1 Percentage of patients with ILI over the epidemiological weeks.

1. ILI: - Influenza-Like Illness: Acute respiratory symptoms <10 days, Fever 38°C, systemic symptoms (myalgia, malaise, ...)
2. ARI: - Acute Respiratory Infection: Acute respiratory symptoms (bronchitis, pharyngitis, rhinitis, pneumonia...) with or without fever.

## SARS-CoV-2 Genomic Surveillance

### The current sequencing strategy

The National Reference Laboratory for Acute Respiratory Infections at LNS continues to improve the representativeness of the pool of sequenced specimens to reach real-time epidemiology, by implementing the following weekly sequencing activities:

- 1) Sequencing specimens from all hospitalized positive cases
- 2) Sequencing specimens from all positive cases from Airport testing program
- 3) Sequencing specimens from all outbreaks and identified clusters
- 4) Systematic sequencing of specimens from reinfections and post-vaccination-infections
- 5) Population sequencing of specimens from representative regions and age groups, to follow the evolution of the different variants in the Luxembourg population.

The representative sequencing sample was based on the minimum number of specimens required to extrapolate prevalence of VOC variants with error rate of 5%. The representative sample was estimated based on the number of positive cases in Luxembourg in week 26 (787). The minimum sample size required to detect prevalence of B.1.617.2 (60,8%) reported in week 25 with an error margin of 5% was estimated to be **251** specimens. The calculation was based on a sample size calculation tool that uses the expected prevalence of the variant in the total population. (Population Proportion - Sample Size - Select Statistical Consultants ([select-statistics.co.uk](http://select-statistics.co.uk))). This number represented a coverage of 31,9%, which exceeds the minimum coverage recommended by ECDC (10%). The number of **non-targeted** specimens from Luxembourgish residents sequenced this week was **315**. Therefore, our sequencing results this week are representative of the circulating variants in Luxembourg.

The starting material used for sequencing is respiratory specimens (nasopharyngeal or oropharyngeal swabs) that have already been tested positive by RT PCR.

The LNS sequencing data sharing strategy includes sharing of the sequencing data with GISAID EpiCov database ([www.gisaid.org](http://www.gisaid.org)) on a periodic basis.

### Sequenced specimens

Last week the microbial genomics platform at the LNS sequenced 637 specimens, with 540 collected in week 26/2021. The sequencing pool referring to Luxembourgish residents represents 65,1% of new infections reported in Luxembourg in week 26/2021.

Among these 540 specimens, 200 specimens were reported to be part of a cluster or outbreak investigation, and 28 specimens were from non-residents (3 specimen overlapping). This leads to 315 specimens, collected in week 26, and being a representative population sequencing sample. In the population representative sample of residents, the frequency for P.1 was 74,3%, while the frequency for B.1.617.2 and B.1.1.7, was 24,4% and 0,95% respectively.

The population sequencing coverage in week 26/2021 was 40% (Figure 2). Based on statistical inference, the frequency of the reported variants in week 26/2021 is **representative** of the circulating variants in Luxembourg with a margin of error of 5%.





Figure 2 Sequence coverage based on total number of positive cases in Luxembourg in between week 52/2020 and week 26/2021.

### Circulating lineage detection

Lineages (variants) have been assigned based on Rambaut *et al* by means of Phylogenetic Assignment of Named Global Outbreak LINEages (pangolin) software (v3.1.5, pangoleARN version 2021-06-15).

The lineage nomenclature system that we use is the one proposed by Rambaut et al. that focuses on actively circulating virus lineages (<https://cov-lineages.org>).

In week 26/2021, in the population representative sample, after removal of cluster samples, and excluding specimens collected from non-residents, there were 4 circulating SARS-CoV-2 variants, the P.1 (74,3%, CI 69,5% - 79,1%), B.1.617.2 (24,4%, CI 19,7% - 29,1%), B.1.1.7 (0,95%, CI 0% - 2%) and B.1.612 (0,3%, CI 0% - 0,9%) as shown in **Figure 3**.



*Figure 3 Number of SARS-CoV-2 variants in representative sample for week 26/2021*

#### Variants of Concern tracker (B.1.1.7, B.1.351, P.1, B.1.525, B.1.617.2)

While an overall 8-fold increase of new infections has been detected, the Gamma (P.1) variant showed a 20-fold increase in case numbers, with 391 new cases (72,4%) in week 26/2021 (by comparison, the week 25/2021 pool had shown 24,1% of this variant). The total case count of sequenced Gamma variant was 537 by week 26/2021.

In week 26/2021, 137 additional cases of the Delta variant B.1.617.2 have been detected. The case count by week 26 for B.1.617.2 rose to 416.

Among specimens collected within the week 26/2021, 6 cases of the Alpha (B.1.1.7) variant have been detected, representing 1,1% of the specimens in the week's sequencing pool (by comparison, the week 25/2021 pool had shown a frequency of 10,1% of this variant). The total case count of sequenced variant Alpha was 6904 by week 26/2021.

In the collection period of week 26/2021, 2 cases of the Beta (B.1.351) variant have been detected, representing 0,37% (by comparison, the week 25/2021 pool had shown 2,5% of this variant). The total case count of sequenced variant B.1.351 was 1192 by week 26/2021.

In week 26/2021, one new case of B.1.525 has been detected. The case count by week 26 for B.1.525 was 50 (Figure 4).

Lineage B.1.1.7 is characterized by several spike protein mutations, including N501Y, H69/V70del and P861H. The variant seems to have a considerable epidemiological impact, as it has a higher transmissibility rate.

Lineage B.1.351 holds numerous spike protein mutations, of which three are located in the receptor binding domain (K417N, E484K and N501Y), and are therefore relevant for antibody binding. As for B.1.1.7, a higher transmissibility rate and viral loads seem to be associated with this variant. Due to the K417N and E484K mutations, an impact on vaccination efficacy and possibility of reinfection is subject to scientific investigation.

Lineage P.1 (descendent of B.1.1.28), initially found in the Amazon region, has a similar mutation profile as the South African variant, including E484K and N501Y. Concerns are, as for the South African variant, higher transmissibility and a decreased protection by neutralizing antibodies.

Lineage B.1.525 carries several mutations of biological significance, including E484K, Q677H and F888L. It does not carry N501Y, but a set of deletions similar to the B.1.1.7 variant.

Lineage B.1.617 is a variant first detected in India and was designated “Under Investigation” on 1<sup>st</sup> April 2021 by Public Health England. It contains a number of spike mutations associated with antigenic escape or found in other variants of concern, including L452R, E484Q and P681R. Subtype B.1.617.2 does not carry S:E484Q and seems to be more transmissible than B.1.1.7 (increasing confidence). Neutralization studies show reductions in cross-neutralizing activity between B.1.1.7 and B.1.351.




Figure 4 Evolution of variants in Sequencing pool of all specimens including targeted sequencing (cluster/contact tracing/ non residents) since first detection of B.1.1.7 in Luxembourg

By week 26/2021, 99,4 % of the variants detected in the sequenced specimen pool are declared as Variants of Concern, including the P.1 (Gamma), the B.1.617.2 (Delta), the B.1.1.7 (Alpha) and B.1.351 (Beta) variants.

#### WHO nomenclature to track VOC

The ReViLux will continue to use the (Pango) system to allow easier visualisation of links between any evolving variants and their ancestor (Figure 5).

WHO label	Pango lineage	GISAIID clade/lineage	Nextstrain clade	Earliest documented samples	Date of designation
Alpha	B.1.1.7	GRY (formerly GR/501Y.V1)	20I/S:501Y.V1	United Kingdom, Sep-2020	18-Dec-2020
Beta	B.1.351	GH/501Y.V2	20H/S:501Y.V2	South Africa, May-2020	18-Dec-2020
Gamma	P.1	GR/501Y.V3	20J/S:501Y.V3	Brazil, Nov-2020	11-Jan-2021
Delta	B.1.617.2	G/452R.V3	21A/S:478K	India, Oct-2020	VOI: 4-Apr-2021 VOC: 11-May-2021

Figure 5 SARS-CoV-2 Variants of Concern and Variants of Interest, updated 31 May 2021 (WHO website)

### Clinically relevant mutations

Currently the LNS genomic surveillance program - independently from lineage calling - notes the occurrence of 13 different known SARS-CoV-2 mutations, assumed to have clinical and epidemiological relevance. The list of observed mutations is being updated continually, based on the appearance and prevalence of SARS-CoV-2 variants.

The following table provides the overall frequencies of these mutations, detected in the lineage-assignable genome sequences, analyzed between 01/SEP/2020 and 04/JULY/2021 (N=14284), as well as the frequencies in week 26/2021.

Mutation	Gene	Genomic Position in reference	Frequency Overall [%]	Frequency Week 26/2021 [%]	Characteristics	Reference
L37F	Nsp6	11081	3,6	2,2	Favored viral infection, higher severity	Aiewsakun 2020
P323L	ORF1ab	14407	88,2	89	Higher severity	Biswas & Mudi 2020
H69/V70del	S gene	21765-21770	48,1	1,5	possible impact on antibody neutralization activity and reinfection; included in "mink" mutation	Kemp 2020
Y144del	S gene	21991-21993	48,7	1,7	possible impact on antibody binding affinity	Dawood 2020
K417N	S gene	22813	8,3	0,4	501Y.V2 / possible impact on antibody binding affinity (escape mutation)	Kemp 2020
E484K	S gene	23012	13,4	68,3	501Y.V2 / possible impact on antibody neutralization activity (escape mutation), improved ACE2 binding affinity	Greaney 2020
N501Y	S gene	23063	56,8	68,4	501Y.V1/V2; Improved ACE2 binding affinity/higher transmissibility	Filip Fratev 2020 COVID-19 Genomics Consortium UK, 2020
D614G	S gene	23402	95,1	96,3	Higher infectivity, higher case fatality rate, higher transmission; replaced original Wuhan strain, became globally dominant form of the virus	Eaaswarkhanth 2020 Becerra-Flores 2020, Hu 2020, Plante 2020
P681H	S gene	23604	45,7	1,5	immediately adjacent to the furin cleavage site, a known location of biological significance	COVID-19 Genomics Consortium UK, 2020
Q57H	ORF3a	25561	23,5	0,9	Higher severity	Biswas & Mudi 2020
N439K	S gene	26143	0,9	0	Improved ACE2 binding affinity	Zhou 2020
R203K	N gene	28880	58	75	Fitness advantage for the virus	Leary 2020
G204R	N gene	28883	57,9	74,9	Fitness advantage for the virus	Leary 2020

## References

Genomic sequencing of SARS-CoV-2. A guide to implementation for maximum impact on public health. WHO, 8 January 2021.

COVID-19 data portal. 2020 (<https://www.covid19dataportal.org/sequences> )

J Hadfield et al. Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics* 2018;34:4121-4123

A Rambaut et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nat Microbiol* 2020;5:1403-1407

<https://github.com/cov-lineages/pangolin>

For more information on lineages visit: <https://cov-lineages.org>

For more information and statistics on Covid-19 infections in Luxembourg visit: <https://covid19.public.lu/en.html>